139 related articles for article (PubMed ID: 36917215)
1. Proton pump Inhibitors and Risk of Enteric Infection in Inflammatory Bowel Disease: A Self-controlled Case Series.
Varma S; Trudeau SJ; Li J; Freedberg DE
Inflamm Bowel Dis; 2024 Jan; 30(1):38-44. PubMed ID: 36917215
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitor Use Before and After a Diagnosis of Inflammatory Bowel Disease.
Singh N; Nugent Z; Singh H; Shaffer SR; Bernstein CN
Inflamm Bowel Dis; 2023 Dec; 29(12):1871-1878. PubMed ID: 36790051
[TBL] [Abstract][Full Text] [Related]
3. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts.
Xia B; Yang M; Nguyen LH; He Q; Zhen J; Yu Y; Di M; Qin X; Lu K; Kuo ZC; He Y; Zhang C; Meng W; Yuan J
Gastroenterology; 2021 Dec; 161(6):1842-1852.e10. PubMed ID: 34389338
[TBL] [Abstract][Full Text] [Related]
4. Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease.
Choden T; Zhang H; Sakuraba A
Ann Med; 2023 Dec; 55(1):2198775. PubMed ID: 37070427
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
6. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
Lu TX; Dapas M; Lin E; Peters T; Sakuraba A
Gut; 2021 Nov; 70(11):2076-2084. PubMed ID: 33334900
[TBL] [Abstract][Full Text] [Related]
7. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection.
Inghammar M; Svanström H; Voldstedlund M; Melbye M; Hviid A; Mølbak K; Pasternak B
Clin Infect Dis; 2021 Jun; 72(12):e1084-e1089. PubMed ID: 33629099
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
Freedberg DE; Salmasian H; Friedman C; Abrams JA
Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
[TBL] [Abstract][Full Text] [Related]
9. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease.
Shah R; Richardson P; Yu H; Kramer J; Hou JK
Digestion; 2017; 95(3):188-193. PubMed ID: 28288458
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection.
Bavishi C; Dupont HL
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1269-81. PubMed ID: 21999643
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
[TBL] [Abstract][Full Text] [Related]
13. Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
Spartz EJ; DeDecker LC; Fansiwala KM; Noorian S; Roney AR; Hakimian S; Sauk JS; Chen PH; Limketkai BN
Aliment Pharmacol Ther; 2024 Jan; 59(1):89-99. PubMed ID: 37873878
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
Vitikainen K; Haapamäki J; Färkkilä M; Anttila VJ; Arkkila P
Scand J Gastroenterol; 2018 Aug; 53(8):947-951. PubMed ID: 30041549
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?
Ben-Eltriki M; Chhabra M; Cassels A; Wright JM
Curr Drug Saf; 2024; 19(2):244-247. PubMed ID: 37496243
[TBL] [Abstract][Full Text] [Related]
16. Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study.
Ikuta K; Nakagawa S; Yamawaki C; Itohara K; Hira D; Imai S; Yonezawa A; Nakagawa T; Sakuragi M; Sato N; Uchino E; Yanagita M; Terada T
BMC Nephrol; 2022 Nov; 23(1):383. PubMed ID: 36451129
[TBL] [Abstract][Full Text] [Related]
17.
Bolukcu S; Hakyemez IN; Gultepe BS; Okay G; Durdu B; Koc MM; Aslan T
Saudi J Gastroenterol; 2019; 25(6):384-389. PubMed ID: 31793457
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Risk Factors Associated With Inflammatory Bowel Disease in Patients Using Proton-Pump Inhibitors: A Population-Based Study.
Onwuzo S; Boustany A; Khaled Abou Zeid H; Hitawala A; Almomani A; Onwuzo C; Lawrence F; Mascarenhas Monteiro J; Ndubueze C; Asaad I
Cureus; 2023 Jan; 15(1):e34088. PubMed ID: 36843811
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease from a teaching hospital.
Li YM; Liao JZ; Jian ZJ; Li HL; Chen X; Liu QX; Liu PL; Wang ZQ; Liu X; Yan Q; Liu WE
J Clin Lab Anal; 2022 Dec; 36(12):e24773. PubMed ID: 36397282
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization With Clostridioides difficile in Pediatric Inflammatory Bowel Disease: a Population-Based Study.
Kuenzig ME; Benchimol EI; Bernstein CN; Bitton A; Carroll MW; Griffiths AM; Kaplan GG; Nguyen GC; Otley AR; Stukel TA; Dummer TJB; El-Matary W; Jacobson K; Jones JL; Lix LM; Mack DR; Murthy SK; Peña-Sánchez JN; Targownik LE; Fung SG; Spruin S; Coward S; Cui Y; Filliter C; Nugent Z; Siddiq S; Singh H;
J Pediatr Gastroenterol Nutr; 2022 Aug; 75(2):173-180. PubMed ID: 35675701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
